Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient With Metastatic Renal Cell Carcinoma and Limited Renal Reserve: A Diagnostic Challenge

By afschroeder • September 25, 2026

Goshtaseb R, Luu Y, Sarmosyan K, Lopez L, Drakaki A. Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient With Metastatic Renal Cell Carcinoma and Limited Renal Reserve: A Diagnostic Challenge. Cureus. 2026 Aug 24;18(8):e115080. doi: 10.7759/cureus.115080. PMID: 42780982; PMCID: PMC13599747.

Tags: anca-associated glomerulonephritis (anca-gn), ANCA-associated vasculitis, Hematology/Oncology, immune checkpoint inhibitor, immune-related adverse event, Nephrology, p-anca positive vasculitis, pembrolizumab, proteinuria, Publications

Related Posts

Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models

Anand SK, Das S, Arias F, Richard KS, Rohilla S, Ghrayeb A, McKinney MP, Wang L, Tan L, Ding J, Kumar D, Pandey N, Lee[...]

Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies

Yarchoan M, Llovet JM, Kelley RK, Finn R, Parikh ND, Tabrizian P, Burgoyne AM, Agopian VG, Sanford NN, Tran Cao HS, Padia SA, Vogel A,[...]

Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial

Shitara K, Wainberg Z, Tabernero J, Van Cutsem E, Coutzac C, De La Fouchardière C, Lee J, Rha SY, Kang YK, Fanning P, Forgie A,[...]